A fully chimeric IgG antibody for ROR1 suppresses ovarian cancer growth in vitro and in vivo.

导出 LinkOut

翻译打印收藏纠错

第一作者： Zhengna,Yin

第一单位： Department of Obstetrics and Gynecology, Fuyang People's Hospital, Fuyang, 236000, China; Department of Obstetrics and Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China.

作者： Zhengna,Yin ^[1] ; Yuan,Mao ^[2] ; Ningzhi,Zhang ^[3] ; Yiping,Su ^[4] ; Jin,Zhu ^[5] ; Hua,Tong ^[4] ; Huilin,Zhang ^[6]

作者单位： Department of Obstetrics and Gynecology, Fuyang People's Hospital, Fuyang, 236000, China; Department of Obstetrics and Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China. ^[1] Department of Hematology and Oncology, Geriatric Hospital of Nanjing Medical University, Jiangsu Province Geriatric Hospital, Nanjing, 210000, China. ^[2] Department of Obstetrics and Gynecology, Fuyang People's Hospital, Fuyang, 236000, China. ^[3] Department of Obstetrics and Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China. ^[4] Huadong Medical Institute of Biotechniques, Nanjing, 210002, China. ^[5] Department of Obstetrics and Gynecology, Women's Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing, 210004, China. Electronic address: zhl068@163.com. ^[6]

关键词 Immunotherapy Monoclonal antibody Ovarian cancer ROR1